p53 protein, MAPK and topoisomerase II α in serous ovarian carcinomas
| Autor: | Šundov, Dinka |
|---|---|
| Přispěvatelé: | Tomić, Snježana, Vrdoljak, Eduard, Jukić, Stanko, Strinić, Tomislav |
| Jazyk: | chorvatština |
| Rok vydání: | 2023 |
| Předmět: |
Ovarian Neoplasms
p53 Genes Novotvorine jajnika BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Pathology Neoplasm Antigens Pathology. Clinical medicine Antigeni novotvorina p53 geni BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Patologija Patologija. Klinička medicina udc:616(043.3) |
| Popis: | Cilj istraživanja. Cilj ovog istraživanja bio je utvrditi razinu imunohistokemijske ispoljenosti p53 proteina, MAPK i topoizomeraze IIα u seroznim karcinomima jajnika niskog i visokog gradusa, te utvrditi njihovu povezanost sa kliničko-patološkim prognostičkim pokazateljima, dužinom slobodnog intervala bez bolesti i ukupnim preživljenjem te odgovorom na kemoterapiju. Materijali i metode. U istraživanje je uključena 81 bolesnica sa seroznim karcinomom jajnika, operirana u razdoblju od 1995. do 2005. godine. Uzorci tumora bojani su imunohistokemijski primjenom protutijela za p53, MAPK i topo IIα. Učinjena je i KRAS/BRAF mutacijska analiza na uzorcima 73 tumora. Rezultati. Deset bolesnica (12.3%) dijagnosticirano je u ranom kliničkom stadiju bolesti. Od 81 seroznog karcinoma, 13.6% morfološki je odgovaralo karcinomu niskog gradusa (tip I tumori), a 86.4% karcinomu visokog gradusa (tip II tumori). Serozni karcinomi niskog i visokog gradusa statistički se značajno razlikuju prema imunohistokemijskom izražaju p53 proteina (P= Background: The aim of this study was to assess the immunohistochemical expression of p53, MAPK and topoisomerase II alpha in ovarian serous carcinomas (OSCs), and their relation with clinicopathological prognostic factors, disease free and overall survival and chemotherapy response. Methods: The study included 81 patients with OSCs who underwent surgery between 1995 and 2005. Formalin fixed paraffin embedded tumour sections were reviewed and examined immunohistochemically using antibodies against p53, MAPK and topoII alpha. KRAS and BRAF mutational analysis was performed on 73 available microdissected samples. Results: Ten patients (12.3%) were diagnosed in early stage of disease. Of 81 cases of OSCs, 13.6% were of low-grade (Type I) and 86.4% were of high-grade (Type II) morphology. We have found statistically significant differences in the immunohistochemical expression of p53 (P= |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|